Please select the option that best describes you:
Topics:
Thoracic Malignancies • Medical Oncology
Are there subsets of patient in which you would choose chemotherapy+pembrolizumab vs pembrolizumab monotherapy in metastatic NSCLC?
Given the results of Keynote 189, is there any benefit of chemotherapy+pembrolizumab in specific subsets of patients in the first line setting?
Answer from: Medical Oncologist at Academic Institution
My take on what to do in the >50% PD-L1 patients from an unapologetic cross-trial comparison of KEYNOTE-024 and the 50% subgroup of KEYNOTE-189: mPFS: 10.3 in KN24, 9.4 in KN189PFS at 12 months: 48% in KN24, 45% in KN189OS at12 months: 70% in KN24, 73% in KN189 Thus, I think chemo does not add...
Sign in or Register to read more